April Logan
YOU?
Author Swipe
View article: Posttransplant Health–economic Impact of Normothermic Machine Perfusion (Back-to-base Model): Advancing Donation After Circulatory Death Liver Transplants With Improved Outcomes and Reduced Wait Times
Posttransplant Health–economic Impact of Normothermic Machine Perfusion (Back-to-base Model): Advancing Donation After Circulatory Death Liver Transplants With Improved Outcomes and Reduced Wait Times Open
Background. The widespread use of normothermic machine perfusion (NMP) has enabled greater utilization of donation after circulatory death (DCD) liver grafts for transplantation. Use of NMP can cost an additional $40 000–$100 000 The aim o…
View article: Pretransplant Midodrine Use—A Risk Factor for Graft Loss at 1 Year in Kidney Transplant Recipients?
Pretransplant Midodrine Use—A Risk Factor for Graft Loss at 1 Year in Kidney Transplant Recipients? Open
The need for Midodrine to maintain blood pressure before kidney transplantation can serve as a marker for inferior graft and patient outcomes at 1-year. Additional studies with more data are needed to further support this theory and adjust…
View article: Determinants of Long Waiting Time to Kidney Transplantation
Determinants of Long Waiting Time to Kidney Transplantation Open
KAS250 has reduced waiting time disparities between SWT and LWT centers at the cost of increased CIT and DGF and reduced allocation efficiency. Significant differences in transplant practice persist between SWT and LWT centers.
View article: Outcomes of Liver Transplantation From Hepatitis C Virus–positive DCD Donors and Its Utilization Among Centers in the United States
Outcomes of Liver Transplantation From Hepatitis C Virus–positive DCD Donors and Its Utilization Among Centers in the United States Open
Background. Donation after circulatory death (DCD) or hepatitis C virus (HCV + ) liver grafts are underused among transplant centers in the United States. The study aimed to evaluate organ utilization and outcomes of liver grafts from DCD …
View article: Variation in DCD Liver Transplant Protocols Among Transplant Centers in the United States
Variation in DCD Liver Transplant Protocols Among Transplant Centers in the United States Open
Background. Variation in donation after circulatory death (DCD) organ recovery and liver transplant practices exist among transplant centers. This study aimed to evaluate these practices among centers in the United States. Methods. Scienti…
View article: Textbook Outcome as a Quality Metric in Living and Deceased Donor Kidney Transplantation
Textbook Outcome as a Quality Metric in Living and Deceased Donor Kidney Transplantation Open
BACKGROUND: Quality in kidney transplantation is measured using 1-year patient and graft survival. Because 1-year patient and graft survival exceed 95%, this metric fails to measure a spectrum of quality. Textbook outcomes (TO) are a compo…
View article: Textbook Outcome as a Quality Metric in Liver Transplantation
Textbook Outcome as a Quality Metric in Liver Transplantation Open
Background. Quality in liver transplantation (LT) is currently measured using 1-y patient and graft survival. Because patient and graft survival rates now exceed 90%, more informative metrics are needed. Textbook outcomes (TOs) describe id…
View article: Dynamic impact of liver allocation policy change on donor utilization
Dynamic impact of liver allocation policy change on donor utilization Open
Liver allocation policy was changed to reduce variance in median MELD scores at transplant (MMaT) in February 2020. "Acuity circles" replaced local allocation. Understanding the impact of policy change on donor utilization is important. Id…
View article: Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia
Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia Open
Cytomegalovirus (CMV) prophylaxis with valganciclovir is the standard of practice in most transplant centers, but treatment-related leukopenia can limit valganciclovir’s use. Therefore, we evaluated letermovir, a novel antiviral agent rece…